Trauma plates with 50x greater fatigue resistance compared to metal offer new treatment options and significant cost-saving potential for healthcare providers.
Integra LifeSciences Holdings Corporation has completed the acquisition of the MicroFrance and Xomed instrument lines from Medtronic.
The FDA has approved various changes to the protocol for InVivo’s ongoing IDE pilot trial for its acute spinal cord injury scaffold.
Dallen Medical Inc., has gained U.S. FDA clearance for its Tensyn™ Band for acromioclavicular joint and coracoacromial ligament repair in shoulder separation.
Reducing tissue slippage is a desirable feature of any laparoscopic cutting device, delivering more consistent results and potentially fewer firings.
Covidien's updated software features a more intuitive interface that helps reduce planning time and enhances airway visualization.
TactiCath Quartz contact-force technology provides physicians with more control of contact force during ablation procedures in order to create more effective lesions in paroxysmal AF treatment.
ReFlow Medical, Inc. has gained FDA clearance for its Wingman35 Crossing Catheter for use in the peripheral vasculature as well as the first U.S. clinical cases with the device.
Zimmer Holdings, Inc., is offering us an advance preview of its future executive leadership team and organizational structure of what is to be called Zimmer Biomet.
The FDA has approved manufacturing process changes to InspireMD's MGuard Prime EPS that were proposed in response to April Voluntary Field Action
More consolidation in the medtech sector, this time in the outsourced manufacturing business, with Creganna-Tactx Medical bolting on medical wire processor Precision Wire Components to its offering.
use of a portable non-invasive open ventilation system resulted in clinically significant improvements in dyspnea scale and the COPD Assessment.
Wright Medical Group, Inc., and Tornier N.V. are to merge in an all stock transaction with a combined equity value of approximately $3.3 billion.
Study results show that PathFinderTG is the most accurate, clinically validated test available for determining risk of malignancy in pancreatic cysts.
Device company CardioKinetix is looking east with the announcement of the first enrollments in PARACHUTE China, a multi-center trial.